AbbVie (ABBV)DoD awarded $3.6K

$3.6K

committed so far

Signed

Jun 18, 2026

Updated

Aug 6, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Feb 3, 2026Federal contract · $5K obligatedDepartment of Defense awarded AbbVie: $4.6K obligated to date
2. Mar 27, 2026CongressDisclosed purchase of ABBV — reported range $15,001 - $50,000
3. Apr 23, 2026Government · Federal Register noticeKimberly Schaff Kiehl: Final Debarment Order
4. Apr 29, 2026Company filing · Form 8-K · ResultsReported its results
5. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
6. May 5, 2026CongressDisclosed sale of ABBV — reported range $1,001 - $15,000
7. May 18, 2026FDARecall: PRED MILD, prednisolone acetate ophthalmic suspension, USP, 0.12%, 10 mL, Sterile, Rx only, Allergen, Inc., an AbbVie company, North Chicago, IL 60064, Product…
8. May 19, 2026Layoff notice · 2525 Dupont Drive Irvine CA 92612Layoff notice filed in CA: 85 employees
9. May 20, 2026FDAFDA drug approval: Venclexta
10. May 21, 2026FDAFDA drug approval: Linzess
11. May 27, 2026FDAFDA drug approval: Decnupaz
12. Jun 3, 2026Government · Federal Register noticeElite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications
13. Jun 8, 2026Government · Federal Register noticeDetermination That Protamine Sulfate (Protamine Sulfate) Intravenous; Solution, 50 Milligrams/5 Milliliters, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
14. Jun 12, 2026FDAFDA drug approval: Skyrizi
15. Jun 18, 2026 · this disclosureFederal contract · $4K obligatedDepartment of Defense awarded AbbVie: $3.6K obligated to date

What came next

1. Jun 26, 2026FDAFDA drug approval: Skyrizi
2. Jun 26, 2026Government · Federal Register noticeDetermination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
3. Jun 29, 2026Government · Federal Register noticeDetermination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
4. Jul 1, 2026Federal contract · $3K obligatedDepartment of Defense awarded AbbVie: $3.3K obligated to date
5. Jul 6, 2026Company filing · Form 8-K · ResultsReported its results
6. Jul 6, 2026Government · Federal Register noticeEndo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
7. Jul 7, 2026Government · Federal Register noticeCertain Antibody Drug Conjugates and Components Thereof and Products Containing the Same; Notice of a Commission Determination Not To Review an Initial Determination Terminating the Investigation; Termination of Investigation
8. Jul 31, 2026Company filing · Form 8-K · ResultsReported its results
9. Aug 14, 2026Insider · Their largest sale since 2023Officer sold ~$8.18M of ABBV shares in the open market
10. Sep 1, 2026Government · Federal Register noticeDetermination That NAMENDA (Memantine Hydrochloride) Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
11. Sep 2, 2026Government · Federal Register noticeDetermination That CARAFATE (Sucralfate) Oral Suspension, 1 Gram/10 Milliliters, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
12. Sep 14, 2026CongressDisclosed sale of ABBV — reported range $15,001 - $50,000
13. Sep 25, 2026FDAFDA drug approval: Juvmo
14. Oct 5, 2026Company filing · Form 8-K · ResultsReported its results

How to read USAspending.gov award record

The obligated amount is money the government has legally committed to pay and has set aside in its accounts. The ceiling, which USAspending calls the potential value, is the most the contract could be worth if every option is exercised and every possible order is placed. The ceiling is a limit, not a payment, and it is often many times the obligated amount.

Full guide: Contract ceiling vs obligated amount: the difference

What else is on file for AbbVie

For AbbVie, OQRO holds 2 insider filings (SEC Form 4 or Form 144), 2 Congress trade reports, 130 fund holdings reports (13F) and 2 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABBV page.

How this filing works

• Contract ceiling vs obligated amount

Other disclosures at AbbVie

• House Clerk periodic transaction reportSep 18, 2026
• SEC Form 13F-HRAug 26, 2026
• SEC Form 13F-HRAug 25, 2026
• SEC Form 4Aug 18, 2026
• SEC Form 13F-HRAug 17, 2026
• SEC Form 144Aug 14, 2026

Everything OQRO holds on this company is on its ABBV page.